Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Time to SARS-CoV-2 Clearance Among Patients with Cancer and COVID-19

View ORCID ProfileWenxin Xu, View ORCID ProfileAndrew J. Piper-Vallillo, View ORCID ProfilePoorva Bindal, Jonathan Wischhusen, Jaymin M. Patel, View ORCID ProfileDaniel B Costa, View ORCID ProfileMary Linton B. Peters
doi: https://doi.org/10.1101/2020.07.23.20161000
Wenxin Xu
Department of Medicine, Division of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wenxin Xu
Andrew J. Piper-Vallillo
Department of Medicine, Division of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andrew J. Piper-Vallillo
Poorva Bindal
Department of Medicine, Division of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Poorva Bindal
Jonathan Wischhusen
Department of Medicine, Division of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jaymin M. Patel
Department of Medicine, Division of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel B Costa
Department of Medicine, Division of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daniel B Costa
Mary Linton B. Peters
Department of Medicine, Division of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mary Linton B. Peters
  • For correspondence: mbpeters@bidmc.harvard.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Question What is the median time to clearance of SARS-CoV-2 among cancer patients according to currently used criteria?

Findings In this single-institution retrospective cohort study, the median time to SARS-CoV-2 clearance was 50 days using the ASCO/CDC criteria of 2 negative RT-PCR assays >24 hours apart. Using alternative criteria of 1 negative RT-PCR assay (UK-NICE) or CDC clinical criteria (10 days after first positive RT-PCR and 3 days after last symptoms), median clearance times were 31 days and 13 days, respectively.

Meaning SARS-CoV-2 clearance times differ substantially depending on criteria used and may be prolonged in cancer patients.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Funding: The work was partially funded by National Institutes of Health/National Cancer Institute grants K08 CA248473 (MLBP) and R37 CA218707 (DBC). Disclosure of Potential Conflicts of Interest: JMP: Received honoraria from Radius, research grant support from Breast Cancer Research Foundation, institutional research support from Genentech, Sanofi, Odonate Therapeutics, all outside submitted work. DBC: Reports personal fees (consulting fees and honoraria) and nonfinancial support (institutional research support) from Takeda/Millennium Pharmaceuticals, and AstraZeneca, and Pfizer, as well as nonfinancial support (institutional research support) from Merck Sharp and Dohme Corporation, Merrimack Pharmaceuticals, Bristol-Myers Squibb, Clovis Oncology, Spectrum Pharmaceuticals and Tesaro, all outside the submitted work. MLBP: Received honoraria from Bayer, Exelixis and Agios, travel support from Halozyme, AstraZeneca and Exelixis, research support from Bayer, institutional research support from Taiho, AstraZeneca, BeiGene, Berg, Merck, all outside the submitted work.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Data collection was performed as part of an institutional COVID-19 registry project and approved by the institutional review board.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Blinded data available for review on request

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted July 24, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Time to SARS-CoV-2 Clearance Among Patients with Cancer and COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Time to SARS-CoV-2 Clearance Among Patients with Cancer and COVID-19
Wenxin Xu, Andrew J. Piper-Vallillo, Poorva Bindal, Jonathan Wischhusen, Jaymin M. Patel, Daniel B Costa, Mary Linton B. Peters
medRxiv 2020.07.23.20161000; doi: https://doi.org/10.1101/2020.07.23.20161000
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Time to SARS-CoV-2 Clearance Among Patients with Cancer and COVID-19
Wenxin Xu, Andrew J. Piper-Vallillo, Poorva Bindal, Jonathan Wischhusen, Jaymin M. Patel, Daniel B Costa, Mary Linton B. Peters
medRxiv 2020.07.23.20161000; doi: https://doi.org/10.1101/2020.07.23.20161000

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (76)
  • Allergy and Immunology (198)
  • Anesthesia (54)
  • Cardiovascular Medicine (492)
  • Dentistry and Oral Medicine (90)
  • Dermatology (56)
  • Emergency Medicine (169)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (213)
  • Epidemiology (5706)
  • Forensic Medicine (3)
  • Gastroenterology (217)
  • Genetic and Genomic Medicine (870)
  • Geriatric Medicine (88)
  • Health Economics (232)
  • Health Informatics (763)
  • Health Policy (394)
  • Health Systems and Quality Improvement (254)
  • Hematology (105)
  • HIV/AIDS (182)
  • Infectious Diseases (except HIV/AIDS) (6498)
  • Intensive Care and Critical Care Medicine (391)
  • Medical Education (118)
  • Medical Ethics (28)
  • Nephrology (93)
  • Neurology (850)
  • Nursing (44)
  • Nutrition (141)
  • Obstetrics and Gynecology (163)
  • Occupational and Environmental Health (263)
  • Oncology (515)
  • Ophthalmology (163)
  • Orthopedics (44)
  • Otolaryngology (107)
  • Pain Medicine (48)
  • Palliative Medicine (21)
  • Pathology (149)
  • Pediatrics (251)
  • Pharmacology and Therapeutics (147)
  • Primary Care Research (114)
  • Psychiatry and Clinical Psychology (972)
  • Public and Global Health (2237)
  • Radiology and Imaging (377)
  • Rehabilitation Medicine and Physical Therapy (174)
  • Respiratory Medicine (313)
  • Rheumatology (109)
  • Sexual and Reproductive Health (81)
  • Sports Medicine (82)
  • Surgery (118)
  • Toxicology (25)
  • Transplantation (34)
  • Urology (42)